Network Pharmacology Based Elucidation of Molecular Mechanisms of Laoke Formula for Treatment of Advanced Non-Small Cell Lung Cancer

Overview

Journal Chin J Integr Med

Date 2024 Jun 28

PMID 38941043

Authors

Yu-Yu Feng

Jin-Feng Liu

Yang Xue

Dan Liu

Xiong-Zhi Wu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the specific pharmacological molecular mechanisms of Laoke Formula (LK) on treating advanced non-small cell lung cancer (NSCLC) based on clinical application, network pharmacology and experimental validation.

Methods: Kaplan-Meier method and Cox regression analysis were used to evaluate the survival benefit of Chinese medicine (CM) treatment in 296 patients with NSCLC in Tianjin Medical University Cancer Institute and Hospital from January 2011 to December 2015. The compounds of LK were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, and the corresponding targets were performed from Swiss Target Prediction. NSCLC-related targets were obtained from Therapeutic Target Database and Comparative Toxicogenomics Database. Key compounds and targets were identified from the compound-target-disease network and protein-protein interaction (PPI) network analysis, respectively. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis were used to predict the potential signaling pathways involved in the treatment of advanced NSCLC with LK. The binding affinities between key ingredients and targets were further verified using molecular docking. Finally, A549 cell proliferation and migration assay were used to evaluate the antitumor activity of LK. Western blot was used to further verify the expression of key target proteins related to the predicted pathways.

Results: Kaplan-Meier survival analysis showed that the overall survival of the CM group was longer than that of the non-CM group (36 months vs. 26 months), and COX regression analysis showed that LK treatment was an independent favorable prognostic factor (P=0.027). Next, 97 components and 86 potential targets were included in the network pharmacology, KEGG and GO analyses, and the results indicated that LK was associated with proliferation and apoptosis. Moreover, molecular docking revealed a good binding affinity between the key ingredients and targets. In vitro, A549 cell proliferation and migration assay showed that the biological inhibition effect was more obvious with the increase of LK concentration (P<0.05). And decreased expressions of nuclear factor κB1 (NF-κB1), epidermal growth factor receptor (EGFR) and AKT serine/threonine kinase 1 (AKT1) and increased expression of p53 (P<0.05) indicated the inhibitory effect of LK on NSCLC by Western blot.

Conclusion: LK inhibits NSCLC by inhibiting EGFR/phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, NFκB signaling pathway and inducing apoptosis, which provides evidence for the therapeutic mechanism of LK to increase overall survival in NSCLC patients.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

Zhu H, Hao J, Niu Y, Liu D, Chen D, Wu X . Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep. 2018; 8(1):7238. PMC: 5940835. DOI: 10.1038/s41598-018-25500-x. View

Zhang X, Liu W, Jiang H, Mao B . Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Am J Chin Med. 2018; 46(5):923-952. DOI: 10.1142/S0192415X18500490. View

Chen Y, Zhu J, Zhang W . Antitumor effect of traditional Chinese herbal medicines against lung cancer. Anticancer Drugs. 2014; 25(9):983-91. DOI: 10.1097/CAD.0000000000000127. View

Liu J, Zhang C, Liu S, Wang X, Wu X, Hao J . Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer. Naunyn Schmiedebergs Arch Pharmacol. 2022; 396(2):365-374. DOI: 10.1007/s00210-022-02316-1. View

Luo X, Zhang Y, Li H, Ren M, Liu Y, Liu Y . Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews. Front Pharmacol. 2022; 13:752978. PMC: 8914111. DOI: 10.3389/fphar.2022.752978. View

Gridelli C, Rossi A, Carbone D, Guarize J, Karachaliou N, Mok T . Non-small-cell lung cancer. Nat Rev Dis Primers. 2016; 1:15009. DOI: 10.1038/nrdp.2015.9. View

10.

Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F . Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2021; 50(D1):D1398-D1407. PMC: 8728281. DOI: 10.1093/nar/gkab953. View

11.

Davis A, Wiegers T, Johnson R, Sciaky D, Wiegers J, Mattingly C . Comparative Toxicogenomics Database (CTD): update 2023. Nucleic Acids Res. 2022; 51(D1):D1257-D1262. PMC: 9825590. DOI: 10.1093/nar/gkac833. View

12.

Daina A, Michielin O, Zoete V . SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019; 47(W1):W357-W364. PMC: 6602486. DOI: 10.1093/nar/gkz382. View

13.

Szklarczyk D, Gable A, Nastou K, Lyon D, Kirsch R, Pyysalo S . The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2020; 49(D1):D605-D612. PMC: 7779004. DOI: 10.1093/nar/gkaa1074. View

14.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

15.

Huang D, Sherman B, Tan Q, Kir J, Liu D, Bryant D . DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007; 35(Web Server issue):W169-75. PMC: 1933169. DOI: 10.1093/nar/gkm415. View

16.

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

17.

Bitencourt-Ferreira G, Pintro V, Filgueira de Azevedo Jr W . Docking with AutoDock4. Methods Mol Biol. 2019; 2053:125-148. DOI: 10.1007/978-1-4939-9752-7_9. View

18.

Seeliger D, de Groot B . Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010; 24(5):417-22. PMC: 2881210. DOI: 10.1007/s10822-010-9352-6. View

19.

Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon L . Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol. 2008; 385(1):249-65. DOI: 10.1016/j.jmb.2008.10.063. View

20.

Milburn C, Deak M, Kelly S, Price N, Alessi D, van Aalten D . Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J. 2003; 375(Pt 3):531-8. PMC: 1223737. DOI: 10.1042/BJ20031229. View